DOI QR코드

DOI QR Code

Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision

  • Oh, In-Jae (Department of Internal Medicine, Chonnam National University Hwasun Hospital) ;
  • Ahn, Sung-Ja (Department of Radiation Oncology, Chonnam National University Hwasun Hospital)
  • Received : 2017.03.08
  • Accepted : 2017.03.22
  • Published : 2017.03.31

Abstract

Locally advanced non-small cell lung cancer (LA-NSCLC) is composed of heterogeneous subgroups that require a multidisciplinary team approach in order to ensure optimal therapy for each patient. Since 2010, the National Comprehensive Cancer Network has recommended chemoradiation therapy (CRT) for bulky mediastinal disease and surgical combination for those patients with single-station N2 involvement who respond to neoadjuvant therapy. According to lung cancer tumor boards, thoracic surgeons make a decision on the resectability of the tumor, if it is determined to be unresectable, concurrent CRT (CCRT) is considered the next choice. However, the survival benefit of CCRT over sequential CRT or radiotherapy alone carries the risk of additional toxicity. Considering severe adverse events that may lead to death, fit patients who are able to tolerate CCRT must be identified by multidisciplinary tumor board. Decelerated approaches, such as sequential CRT or high-dose radiation alone may be a valuable alternative for patients who are not eligible for CCRT. As a new treatment strategy, investigators are interested in the application of the innovative radiation techniques, trimodality therapy combining surgery after high-dose definitive CCRT, and the combination of radiation with targeted or immunotherapy agents. The updated results and on-going studies are thoroughly reviewed in this article.

Keywords

References

  1. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90. https://doi.org/10.1200/JCO.2009.26.2543
  2. Dehing-Oberije C, De Ruysscher D, van der Weide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-44. https://doi.org/10.1016/j.ijrobp.2007.07.2323
  3. Ademuyiwa FO, Johnson CS, White AS, et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer 2007;8:478-82. https://doi.org/10.3816/CLC.2007.n.031
  4. Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26:1091-101. https://doi.org/10.1093/annonc/mdu540
  5. Ellis G, Whitehead MA, Robinson D, O'Neill D, Langhorne P. Comprehensive geriatric assessment for older adults admitted to hospital: meta-analysis of randomised controlled trials. BMJ 2011;343:d6553. https://doi.org/10.1136/bmj.d6553
  6. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011;103:1452-60. https://doi.org/10.1093/jnci/djr325
  7. Baumann M, Herrmann T, Koch R, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011;100:76-85. https://doi.org/10.1016/j.radonc.2011.06.031
  8. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 2015;16:187-99. https://doi.org/10.1016/S1470-2045(14)71207-0
  9. Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-704. https://doi.org/10.1200/JCO.2006.07.3569
  10. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-60. https://doi.org/10.1200/JCO.2008.17.7840
  11. Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSGLU05-04. J Clin Oncol 2015;33:2660-6. https://doi.org/10.1200/JCO.2014.60.0130
  12. Schild SE, Vokes EE. Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancer. Ann Oncol 2016;27:590-9. https://doi.org/10.1093/annonc/mdv621
  13. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, populationbased study. Ann Oncol 2009;20:98-102.
  14. Kim YH, Ahn SJ, Kim YC, et al. Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation. Jpn J Clin Oncol 2016;46:144-51.
  15. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011;378:1079-88. https://doi.org/10.1016/S0140-6736(11)60780-0
  16. Takigawa N, Kiura K, Segawa Y, et al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol 2011;6:1087-91. https://doi.org/10.1097/JTO.0b013e318213f86a
  17. Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014;32:2595-603. https://doi.org/10.1200/JCO.2013.54.8347
  18. Movsas B, Hu C, Sloan J, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-smallcell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial. JAMA Oncol 2016;2:359-67. https://doi.org/10.1001/jamaoncol.2015.3969
  19. Ramroth J, Cutter DJ, Darby SC, et al. Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 2016;96:736-747. https://doi.org/10.1016/j.ijrobp.2016.07.022
  20. Yap ML, Sun A, Higgins J, et al. Adaptive dose escalation using serial four-dimensional positron emission tomography/computed tomography scans during radiotherapy for locally advanced non-small cell lung cancer. Clin Oncol (R Coll Radiol) 2016;28:e199-e205. https://doi.org/10.1016/j.clon.2016.08.011
  21. Barriger RB, Fakiris AJ, Hanna N, Yu M, Mantravadi P, McGarry RC. Dose-volume analysis of radiation pneumonitis in nonsmall-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel. Int J Radiat Oncol Biol Phys 2010;78:1381-6. https://doi.org/10.1016/j.ijrobp.2009.09.030
  22. Marks LB, Bentzen SM, Deasy JO, et al. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010;76(3 Suppl):S70-6. https://doi.org/10.1016/j.ijrobp.2009.06.091
  23. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-smallcell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35:56-62.
  24. Farr KP, Kallehauge JF, Moller DS, et al. Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: a prospective study. Radiother Oncol 2015;117:9-16. https://doi.org/10.1016/j.radonc.2015.08.005
  25. Hodge CW, Tome WA, Fain SB, Bentzen SM, Mehta MP. On the use of hyperpolarized helium MRI for conformal avoidance lung radiotherapy. Med Dosim 2010;35:297-303. https://doi.org/10.1016/j.meddos.2009.09.004
  26. Vinogradskiy Y, Koo PJ, Castillo R, et al. Comparison of 4-dimensional computed tomography ventilation with nuclear medicine ventilation-perfusion imaging: a clinical validation study. Int J Radiat Oncol Biol Phys 2014;89:199-205. https://doi.org/10.1016/j.ijrobp.2014.01.009
  27. Speirs CK, Rehman S, Molotievschi A, et al. Comprehensive analysis of dosimetric predictors of overall survival for stage III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy. Int J Radiat Oncol Biol Phys 2014;90(1 Suppl);S667.
  28. Tucker SL, Liu A, Gomez D, et al. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol 2016;119:495-500. https://doi.org/10.1016/j.radonc.2016.04.025
  29. Chang JY, Jabbour SK, De Ruysscher D, et al. Consensus statement on proton therapy in early-stage and locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2016;95:505-16. https://doi.org/10.1016/j.ijrobp.2016.01.036
  30. Nguyen QN, Ly NB, Komaki R, et al. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage IIIII inoperable non-small cell lung cancer. Radiother Oncol 2015;115:367-72. https://doi.org/10.1016/j.radonc.2015.05.014
  31. Lee H, Ahn YC, Pyo H, et al. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. Ann Surg Oncol 2014;21:2083-90. https://doi.org/10.1245/s10434-014-3540-x
  32. Ziel E, Hermann G, Sen N, et al. Survival benefit of surgery after chemoradiotherapy for stage III (N0-2) non-small-cell lung cancer is dependent on pathologic nodal response. J Thorac Oncol 2015;10:1475-80. https://doi.org/10.1097/JTO.0000000000000639
  33. Sonett JR, Krasna MJ, Suntharalingam M, et al. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation. Ann Thorac Surg 1999;68:316-20. https://doi.org/10.1016/S0003-4975(99)00593-7
  34. Cerfolio RJ, Bryant AS, Jones VL, Cerfolio RM. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 2009;35:718-23. https://doi.org/10.1016/j.ejcts.2008.12.029
  35. Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 2005;80:1224-30. https://doi.org/10.1016/j.athoracsur.2005.02.091
  36. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86. https://doi.org/10.1016/S0140-6736(09)60737-6
  37. Ahn S, Na K, Kim Y, et al. Surgical Salvation after full-dose concurrent chemoradiation in patients with locally advanced non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2014;90(1 Suppl):S619.
  38. Suntharalingam M, Paulus R, Edelman MJ, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2012;84:456-63. https://doi.org/10.1016/j.ijrobp.2011.11.069
  39. Senan S, Brade A, Wang LH, et al. PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-smallcell lung cancer. J Clin Oncol 2016;34:953-62. https://doi.org/10.1200/JCO.2015.64.8824
  40. Tam K, Daly M, Kelly K. Treatment of locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am 2017;31:45-57. https://doi.org/10.1016/j.hoc.2016.08.009
  41. Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011;29:2312-8. https://doi.org/10.1200/JCO.2010.31.7875
  42. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6. https://doi.org/10.1200/JCO.2007.14.4824
  43. Wozniak AJ, Moon J, Thomas CR Jr, et al. A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III nonsmall-cell lung cancer: SWOG S0533. Clin Lung Cancer 2015;16:340-7. https://doi.org/10.1016/j.cllc.2014.12.014
  44. Saxena A, Becker D, Preeshagul I, Lee K, Katz E, Levy B. Therapeutic effects of repurposed therapies in non-small cell lung cancer: what is old is new again. Oncologist 2015;20:934-45. https://doi.org/10.1634/theoncologist.2015-0064
  45. Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III nonsmall-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68. https://doi.org/10.1016/S1470-2045(13)70510-2
  46. Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007;83:819-25. https://doi.org/10.1080/09553000701481816
  47. Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-88. https://doi.org/10.1158/1078-0432.CCR-09-0265
  48. Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy 2015;7:967-80. https://doi.org/10.2217/imt.15.65

Cited by

  1. Application of the new 8th TNM staging system for non-small cell lung cancer: treated with curative concurrent chemoradiotherapy vol.12, pp.None, 2017, https://doi.org/10.1186/s13014-017-0848-2
  2. Multidisciplinary management improves survival at 1 year after surgical treatment for non-small-cell lung cancer: a propensity score-matched study† vol.53, pp.6, 2017, https://doi.org/10.1093/ejcts/ezx464
  3. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary c vol.55, pp.2, 2017, https://doi.org/10.4103/ijc.ijc_469_17
  4. Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer vol.110, pp.2, 2017, https://doi.org/10.1111/cas.13890
  5. Less of a good thing - the paradox of reduced multidisciplinary team decision-making : Comment on Behrendt et al., p. 262-269 vol.48, pp.3, 2019, https://doi.org/10.1024/0301-1526/a000782
  6. High-Dose Thoracic Re-irradiation of Lung Cancer Using Highly Conformal Radiotherapy Is Effective with Acceptable Toxicity vol.51, pp.3, 2017, https://doi.org/10.4143/crt.2018.472
  7. Low Prognostic Nutritional Index Predicts Poor Clinical Outcomes in Patients with Stage IIIB Non-small-cell Lung Carcinoma Undergoing Chemoradiotherapy vol.12, pp.None, 2020, https://doi.org/10.2147/cmar.s248034
  8. Predictors of chemoradiotherapy versus single modality therapy and overall survival among patients with unresectable, stage III non-small cell lung cancer vol.15, pp.3, 2017, https://doi.org/10.1371/journal.pone.0230444